ANI PHARMACEUTICALS, INC Accrued Liabilities, Current
ANI PHARMACEUTICALS, INC (ANIP) had Accrued Liabilities, Current of $16.57 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-07
- 2026-06-30: Accrued Liabilities, Current $16.57M.
- 2026-03-31: Accrued Liabilities, Current $13.73M.
- 2025-12-31: Accrued Liabilities, Current $16.97M; Accrued Liabilities, Current as first filed $16.80M.
- 2025-09-30: Accrued Liabilities, Current $13.95M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $16.57M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $13.73M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $16.97M 10-Q · filed 2026-08-07 | $16.80M 10-K · filed 2026-02-27 |
| 2025-09-30 | $13.95M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $14.76M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $12.03M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $13.73M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $17.81M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $6.92M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $7.43M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $5.61M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $5.23M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $5.34M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $4.80M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $5.39M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $4.73M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $11.51M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $8.13M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $7.65M 10-K · filed 2023-03-09 | $7.56M 10-K · filed 2022-03-15 |
| 2021-09-30 | $4.89M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $11.58M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $2.38M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $2.46M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $2.53M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $3.07M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $4.38M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.36M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $3.37M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $2.42M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $3.07M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.71M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $2.82M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $1.86M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $2.61M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $1.57M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $2.74M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $1.56M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $2.09M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $927.00K 10-K · filed 2018-02-27 | |
| 2016-09-30 | $2.02M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $770.00K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.73M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $617.00K 10-K · filed 2017-03-02 | |
| 2015-09-30 | $2.22M 10-Q · filed 2015-11-03 | |
| 2015-06-30 | $1.17M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $1.90M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $567.00K 10-K · filed 2016-02-23 | $1.27M 10-K · filed 2015-02-23 |
| 2014-09-30 | $3.89M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $1.13M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $1.01M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $327.00K 10-K · filed 2015-02-23 | $1.33M 10-K · filed 2014-02-28 |
| 2013-09-30 | $1.34M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $1.04M 10-Q · filed 2013-08-09 | |
| 2012-12-31 | $927.00K 10-K · filed 2014-02-28 | $555.63K 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |